Migraine Market Forecast
Buy Now : Market Research
Introduction
After 4 years of steady growth, the migraine market across the seven major regions was valued at $4.6 billion in 2008. However, following US patent expiries of both the acute migraine market leading brand, Imitrex (sumatriptan; GlaxoSmithKline), and leading prophylactic Topamax (topiramate; Johnson & Johnson), the market value plummeted by almost $1.5 billion from 2008 to $3.6 billion in 2009.
Migraine Market Forecast
Reasons to Purchase
- Quantify the current and future size of the migraine market.
- Understand the country-specific impact of key events in the migraine market during the forecast period 2010 to 2019.
- Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2010 to 2019.
Related Reports
- Migraine Therapeutics – Pipeline Assessment and Market Forecasts to 2016
- Migraine – Drug Pipeline Analysis and Market Forecasts to 2016
- Forecast Insight: Migraine – Generic incursion inhibits market growth
- Migraine – Pipeline Review, Q4 2010
- Disease and Therapy Review: Migraine
- Migraine Therapy Area Pipeline Report
- Pipeline and Commercial Insight: Migraine – Challenges ahead for first-in-class developments
- Central Nervous System Migraine Therapy Area Pipeline Report
- Active Electronically-Scanned Array Radars-Worldwide & Regional Market Forecasts (Systems, TRMs, MMICs) Forecasts to 2015
- Global Biometrics Technology Market (2010-2015) – Market Forecast by Products, End-User Application and Geography
